The Pharmacogenetics CORE integrates molecular genetics into the design and execution of the drug administration and clinical trials of pharmacotherapies for cocaine and methamphetamine dependence. The CORE will provide DNA isolation and DNA genotyping of cocaine- or methamphetamine-dependent patients from ongoing and completed clinical pharmacotherapy trials. Genetic variants and copy number variants (CNVs) will be analyzed for significant associations with response to pharmacotherapeutic treatment regimes. DNA samples will be evaluated for associations of 1) single nucleotide polymorphisms (SNPs), 2) copy number variants (CNVs), and 3) insertion/deletion variants with response to pharmacotherapy. As indicated in our Preliminary Data, we have started the examination ofthe CNVs. Searches ofthe literature and of bioinformatic databases will be conducted to translate the findings about the genetic associations with pharmacological responses into human studies. Genes with significantly associated variants identified from the bioinformatic searches will then be used in prospective pharmacogenetic selection of patients for the matching of these patients to the most appropriate of many available potential anti-addiction medications for further placebo controlled testing in either human laboratory drug administration or clinical trial studies.

Public Health Relevance

The Pharmacogentics CORE will allow us to understand the genetic components that may influence a person's response to pharmacotherapy. The results of this research should allow the tailoring of treatment to each individual person.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1-SXC-E)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
United States
Zip Code
Wachman, Elisha M; Hayes, Marie J; Lester, Barry M et al. (2014) Epigenetic variation in the mu-opioid receptor gene in infants with neonatal abstinence syndrome. J Pediatr 165:472-8
Graham, David P; Nielsen, David A; Kosten, Thomas R et al. (2014) Examining the utility of using genotype and functional biology in a clinical pharmacology trial: pilot testing dopamine ?-hydroxylase, norepinephrine, and post-traumatic stress disorder. Psychiatr Genet 24:181-2
Spellicy, C J; Harding, M J; Hamon, S C et al. (2014) A variant in ANKK1 modulates acute subjective effects of cocaine: a preliminary study. Genes Brain Behav 13:559-64
Mahoney 3rd, James J; De La Garza 2nd, Richard; Jackson, Brian J et al. (2014) The relationship between sleep and drug use characteristics in participants with cocaine or methamphetamine use disorders. Psychiatry Res 219:367-71
Liu, Shijing; Green, Charles E; Lane, Scott D et al. (2014) The influence of dopamine ?-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study. Pharmacogenet Genomics 24:370-3
Mahoney 3rd, James J; Newton, Thomas F; Omar, Yasmine et al. (2013) The relationship between lifetime stress and addiction severity in cocaine-dependent participants. Eur Neuropsychopharmacol 23:351-7
Brewer 3rd, Alex J; Mahoney 3rd, James J; Nerumalla, Chandra S et al. (2013) The influence of smoking cigarettes on the high and desire for cocaine among active cocaine users. Pharmacol Biochem Behav 106:132-6
Kosten, Thomas R; Domingo, Coreen B; Hamon, Sara C et al. (2013) DBH gene as predictor of response in a cocaine vaccine clinical trial. Neurosci Lett 541:29-33
Haile, Colin N; Kosten, Thomas R (2013) Pharmacotherapy for stimulant-related disorders. Curr Psychiatry Rep 15:415
Ross, Elizabeth L; Yoon, Jin H; Mahoney 3rd, James J et al. (2013) The impact of self-reported life stress on current impulsivity in cocaine dependent adults. Prog Neuropsychopharmacol Biol Psychiatry 46:113-9

Showing the most recent 10 out of 39 publications